Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep - PubMed (original) (raw)
Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep
J C Morrill et al. Vaccine. 1991 Jan.
Abstract
A previous study demonstrated that a mutagen-attenuated Rift Valley fever virus (RVFV) vaccine, RVF MP-12, was immunogenic and non-abortogenic when ewes, 90-110 days pregnant, were inoculated with 5 x 10(5) plaque-forming units (p.f.u.) of the virus strain. The ewes delivered live, healthy lambs that had no neutralizing antibody to RVFV until after they had ingested colostrum. To assess further the safety and protective capability of this candidate vaccine, six pregnant ewes were inoculated with 5 x 10(3) p.f.u. of RVF MP-12 and challenged with 5 x 10(5) p.f.u. of virulent ZH-501 strain of RVFV 30 days later. No viraemia was detected after vaccination or challenge and all six ewes delivered live, healthy lambs. Those lambs tested before their nursing did not have neutralizing antibody to RVFV but quickly acquired antibody titres of 1:320 to greater than or equal to 1:10,240 after ingesting colostrum. To test the safety of the RVF MP-12 immunogen in neonates, lambs less than or equal to 7 days old, born to unvaccinated ewes, were inoculated with 5 x 10(5) p.f.u. of RVF MP-12. With the exception of brief pyrexia in 18 of 26 lambs, and a transient low-titred viraemia in 16 of 26 lambs after inoculation, no untoward effects were observed. Serum-neutralizing antibody to RVFV was detected 5-7 days after inoculation. Lambs vaccinated with either 5 x 10(5) or 5 x 10(3) p.f.u. of RVF MP-12 were protected against virulent RVFV challenge at 14 days postvaccination.
Similar articles
- Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids.
Morrill JC, Mebus CA, Peters CJ. Morrill JC, et al. Am J Vet Res. 1997 Oct;58(10):1110-4. Am J Vet Res. 1997. PMID: 9328663 Clinical Trial. - Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle.
Morrill JC, Mebus CA, Peters CJ. Morrill JC, et al. Am J Vet Res. 1997 Oct;58(10):1104-9. Am J Vet Res. 1997. PMID: 9328662 Clinical Trial. - Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent rift valley fever virus.
Morrill JC, Peters CJ. Morrill JC, et al. J Infect Dis. 2011 Jul 15;204(2):229-36. doi: 10.1093/infdis/jir249. J Infect Dis. 2011. PMID: 21673033 - Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.
Ikegami T. Ikegami T. Expert Rev Vaccines. 2017 Jun;16(6):601-611. doi: 10.1080/14760584.2017.1321482. Epub 2017 May 2. Expert Rev Vaccines. 2017. PMID: 28425834 Free PMC article. Review. - Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates.
Terasaki K, Tercero BR, Makino S. Terasaki K, et al. Virus Res. 2016 May 2;216:55-65. doi: 10.1016/j.virusres.2015.05.012. Epub 2015 May 27. Virus Res. 2016. PMID: 26022573 Free PMC article. Review.
Cited by
- Using RNAseq to Uncover Transcriptional and Splicing Differences in Host Cells During Rift Valley Fever Virus Infection.
White LA, Havranek KE, Lodmell JS. White LA, et al. Methods Mol Biol. 2024;2824:373-383. doi: 10.1007/978-1-0716-3926-9_23. Methods Mol Biol. 2024. PMID: 39039424 - Vaccine strains of Rift Valley fever virus exhibit attenuation at the maternal-fetal placental interface.
McMillen CM, Megli C, Radisic R, Skvarca LB, Hoehl RM, Boyles DA, McGaughey JJ, Bird BH, McElroy AK, Hartman AL. McMillen CM, et al. J Virol. 2024 Aug 20;98(8):e0098324. doi: 10.1128/jvi.00983-24. Epub 2024 Jul 17. J Virol. 2024. PMID: 39016561 - Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates.
Alkan C, Jurado-Cobena E, Ikegami T. Alkan C, et al. NPJ Vaccines. 2023 Nov 4;8(1):171. doi: 10.1038/s41541-023-00769-w. NPJ Vaccines. 2023. PMID: 37925544 Free PMC article. Review. - Safety and immunogenicity of inactivated Rift Valley Fever Smithburn viral vaccine in sheep.
Matsiela MS, Naicker L, Khoza T, Mokoena N. Matsiela MS, et al. Virol J. 2023 Oct 3;20(1):221. doi: 10.1186/s12985-023-02180-2. Virol J. 2023. PMID: 37789354 Free PMC article. - Rift Valley Fever Virus-Infection, Pathogenesis and Host Immune Responses.
Nair N, Osterhaus ADME, Rimmelzwaan GF, Prajeeth CK. Nair N, et al. Pathogens. 2023 Sep 19;12(9):1174. doi: 10.3390/pathogens12091174. Pathogens. 2023. PMID: 37764982 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources